Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
Special Offer: Just $199
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
NASDAQ:DNLI

Denali Therapeutics - DNLI Stock Forecast, Price & News

$28.83
-1.14 (-3.80%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$28.58
▼
$30.71
50-Day Range
$25.97
▼
$33.92
52-Week Range
$20.24
▼
$48.46
Volume
522,490 shs
Average Volume
663,442 shs
Market Capitalization
$3.92 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.17

Denali Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
77.5% Upside
$51.17 Price Target
Short Interest
Bearish
6.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
0.93mentions of Denali Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$880,590 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.60) to ($2.99) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

298th out of 1,040 stocks

Biological Products, Except Diagnostic Industry

44th out of 175 stocks

See Top Rated MarketRank™ Stocks Here
DNLI stock logo

About Denali Therapeutics (NASDAQ:DNLI) Stock

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Receive DNLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DNLI Stock News Headlines

November 9, 2022 | finance.yahoo.com
Denali Therapeutics Third Quarter 2022 Earnings: Misses Expectations
November 4, 2022 | finance.yahoo.com
Denali (DNLI) Lags Q3 Earnings Estimates, Pipeline in Focus
November 4, 2022 | finance.yahoo.com
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
November 4, 2022 | finance.yahoo.com
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates
November 4, 2022 | finance.yahoo.com
Analysts' Revenue Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Are Surging Higher
November 2, 2022 | finance.yahoo.com
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
November 1, 2022 | finance.yahoo.com
Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN
October 29, 2022 | seekingalpha.com
Denali Therapeutics: Two Shots On Goal For Parkinson's Disease Treatment
October 25, 2022 | benzinga.com
Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
October 25, 2022 | finance.yahoo.com
Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 19, 2022 | finance.yahoo.com
Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock
October 18, 2022 | marketwatch.com
Denali Therapeutics Shares Decline 14% on Proposed Stock Offering
October 10, 2022 | finance.yahoo.com
Investors in Denali Therapeutics (NASDAQ:DNLI) have made a decent return of 100% over the past three years
October 3, 2022 | technews.tmcnet.com
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson's Disease Associated with LRRK2 Pathogenic Mutations
September 29, 2022 | finance.yahoo.com
Denali Therapeutics Inc. (DNLI) Moves 17.7% Higher: Will This Strength Last?
September 7, 2022 | finance.yahoo.com
Why Is Denali Therapeutics Inc. (DNLI) Down 27.4% Since Last Earnings Report?
August 31, 2022 | finance.yahoo.com
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022
August 9, 2022 | finance.yahoo.com
Denali (DNLI) Q2 Earnings Beat, Pipeline Progress in Focus
August 8, 2022 | finance.yahoo.com
Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
June 27, 2022 | finance.yahoo.com
We Think Denali Therapeutics (NASDAQ:DNLI) Can Afford To Drive Business Growth
June 1, 2022 | finance.yahoo.com
Biogen (BIIB), Denali Begin Mid-Stage Study on Parkinson's Drug
May 31, 2022 | seekingalpha.com
Denali Therapeutics, Biogen begin phase 2 study of BIIB122 to treat Parkinson’s disease
May 12, 2022 | finance.yahoo.com
Broker Revenue Forecasts For Denali Therapeutics Inc. (NASDAQ:DNLI) Are Surging Higher
May 5, 2022 | finance.yahoo.com
Denali Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
May 5, 2022 | finance.yahoo.com
AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Misses Revenue Estimates
See More Headlines
Receive DNLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DNLI Company Calendar

Last Earnings
11/03/2022
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DNLI
CUSIP
N/A
CIK
1714899
Web
www.denalitherapeutics.com
Phone
(615) 866-8548
Fax
N/A
Employees
380
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$51.17
High Stock Price Forecast
$82.00
Low Stock Price Forecast
$38.00
Forecasted Upside/Downside
+77.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-290,580,000.00
Net Margins
-273.34%
Pretax Margin
-273.84%
Return on Equity
-33.85%
Return on Assets
-23.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.16
Quick Ratio
3.16

Sales & Book Value

Annual Sales
$48.66 million
Price / Sales
80.47
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.88 per share
Price / Book
3.66

Miscellaneous

Outstanding Shares
135,814,000
Free Float
118,566,000
Market Cap
$3.92 billion
Optionable
Optionable
Beta
1.46

Key Executives

  • Dr. Ryan J. Watts Ph.D. (Age 46)
    Co-Founder, Pres, CEO & Director
    Comp: $1.13M
  • Dr. Alexander O. Schuth M.D.Dr. Alexander O. Schuth M.D. (Age 49)
    Co-Founder, CFO, COO & Sec.
    Comp: $755.81k
  • Dr. Marc Tessier-Lavigne Ph.D.Dr. Marc Tessier-Lavigne Ph.D. (Age 62)
    Co-Founder, Chairman of Scientific Advisory Board & Independent Director
    Comp: $58.14k
  • Dr. Carole Ho M.D. (Age 49)
    Chief Medical Officer & Head of Devel.
    Comp: $769.39k
  • Mr. Steve Edward Krognes (Age 54)
    Treasurer & Director
    Comp: $813.44k
  • Mr. Tyler M. Nielsen (Age 44)
    Sr. VP of Corp. Fin.
  • Dr. Dana Andersen
    Chief Technical and Manufacturing Officer
  • Mr. Joe Lewcock
    Chief Scientific Officer
  • Dr. Laura Hansen
    VP of Investor Relations
  • Mr. Chris Walsh
    Gen. Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













DNLI Stock - Frequently Asked Questions

Should I buy or sell Denali Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DNLI shares.
View DNLI analyst ratings or view top-rated stocks.

What is Denali Therapeutics' stock price forecast for 2023?

6 brokers have issued 1-year price objectives for Denali Therapeutics' shares. Their DNLI share price forecasts range from $38.00 to $82.00. On average, they expect the company's stock price to reach $51.17 in the next year. This suggests a possible upside of 78.2% from the stock's current price.
View analysts price targets for DNLI or view top-rated stocks among Wall Street analysts.

How have DNLI shares performed in 2022?

Denali Therapeutics' stock was trading at $44.60 on January 1st, 2022. Since then, DNLI shares have decreased by 35.6% and is now trading at $28.71.
View the best growth stocks for 2022 here.

When is Denali Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our DNLI earnings forecast.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) posted its earnings results on Thursday, November, 3rd. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by $0.01. The business had revenue of $3.56 million for the quarter, compared to analysts' expectations of $10.06 million. Denali Therapeutics had a negative trailing twelve-month return on equity of 33.85% and a negative net margin of 273.34%.

What is Ryan Watts' approval rating as Denali Therapeutics' CEO?

1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Denali Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), NVIDIA (NVDA), Invitae (NVTA) and Pretium Resources (PVG).

When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (11.93%), BlackRock Inc. (6.33%), Vanguard Group Inc. (6.19%), Temasek Holdings Private Ltd (4.11%), State Street Corp (3.09%) and ARCH Venture Management LLC (2.70%). Insiders that own company stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends.

How do I buy shares of Denali Therapeutics?

Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $28.71.

How much money does Denali Therapeutics make?

Denali Therapeutics (NASDAQ:DNLI) has a market capitalization of $3.90 billion and generates $48.66 million in revenue each year. The company earns $-290,580,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

How many employees does Denali Therapeutics have?

The company employs 380 workers across the globe.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.denalitherapeutics.com. The company can be reached via phone at (615) 866-8548 or via email at hansen@dnli.com.

This page (NASDAQ:DNLI) was last updated on 11/28/2022 by MarketBeat.com Staff